X
<

Where Sanofi Stands after the 3Q17 Results

PART:
1 2 3 4 5 6 7 8
Part 4
Where Sanofi Stands after the 3Q17 Results PART 4 OF 8

This Sanofi Franchise Reported Double-Digit Growth in 3Q17

Sanofi Genzyme  

Sanofi’s (SNY) Sanofi Genzyme franchise includes specialty care product revenues. The franchise reported revenue growth of 12.5% at constant exchange rates to 1.63 billion euros, including the sales from emerging markets.

After excluding the revenues for emerging markets, the Sanofi Genzyme franchise reported revenue growth of 13.9% at constant exchange rates to 1.39 billion euros for 3Q17.

This Sanofi Franchise Reported Double-Digit Growth in 3Q17

Interested in SNY? Don't miss the next report.

Receive e-mail alerts for new research on SNY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Genzyme portfolio

Sanofi Genzyme includes the following specialty care products:

  • multiple sclerosis drugs
  • oncology products
  • immunology products
  • rare diseases products

For 3Q17, Sanofi Genzyme’s growth of 13.9% at constant exchange rates was driven by a rise in sales of the multiple sclerosis drugs Aubagio and Lemtrada, in addition to rare disease drugs like Cerdelga, Fabrazyme, Myozyme, and Aldurazyme. The franchise also saw growth in oncology product sales like Jevtana, Mozobil, and Zaltrap and in immunology products like Dupixent and Kevzara.

Multiple sclerosis drugs

Aubagio and Lemtrada—two drugs from Sanofi’s multiple sclerosis portfolio—saw combined revenue (including in emerging markets) growth of 15.7% at constant exchange rates to 495 million euros for 3Q17.

Excluding the emerging markets, the combined revenues of these drugs rose 15.5% at constant exchange rates to 481 million euros.

Rare diseases

Sanofi’s rare disease drugs include Aldurazyme, Cerdelga, Cerezyme, Febrazyme, and Myozyme and reported revenue growth of 2.7% at constant exchange rates to 698 million euros, including the revenues from emerging markets.

Excluding emerging markets, the revenues from these rare disease products rose to 570 million euros in 3Q17, driven by increased sales of Cerdelga, Myozyme, and Fabrazyme.

Oncology

Sanofi’s oncology franchise includes Eloxatine, Jevtana, Mozobil, Taxotere, Thymoglobulin, and Zaltrap and rose 5% at constant exchange rates to 363 million euros in 3Q17, including revenues from emerging markets.

Excluding emerging markets, these oncology drug revenues rose 3.8% to 262 million euros in 3Q17, driven by increased sales of Jevtana, Mozobil, and Zaltrap.

Immunology

Dupixent and Kevraza—two drugs in Sanofi’s immunology franchise—saw combined revenues of 77 million euros in 3Q17, driven by an increase in the US sales of Dupixent.

Notably, the BLDRS Developed Markets 100 ADR ETF (ADRD) has 18.5% of its total investments in healthcare, with 5.2% in Novartis AG ADR (NVS), 2.5% in Sanofi ADR (SNY), 2.2% in Novo Nordisk ADR (NVO), and 2.1% in GlaxoSmithKline ADR (GSK).

X

Please select a profession that best describes you: